trending Market Intelligence /marketintelligence/en/news-insights/trending/kSLC55ONIXtoo7dbvcOFOA2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Blueprint Medicines starts rolling submission of lung cancer drug to US FDA

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Blueprint Medicines starts rolling submission of lung cancer drug to US FDA

Blueprint Medicines Corp. started a rolling submission for U.S Food and Drug Administration approval of the lung cancer treatment pralsetinib.

The Cambridge, Mass.-based company has begun the new drug application process for the oral medicine as a treatment for non-small cell lung cancer patients with a mutation in the RET gene. The gene's mutations have been identified in several types of cancer, including lung cancer.

Pralsetinib was submitted to the FDA after early-stage trial results showed that 61% of the lung cancer patients with this gene mutation responded to the treatment.

Blueprint expects to complete the submission in the first quarter of 2020.

The company also intends to submit pralsetinib to the FDA in the second quarter of 2020 for treating a type of thyroid cancer.